Has David Alpers received payments from drug or device companies?

Yes. Drug and device makers reported $616,196 in general payments to David Alpers across 248 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Alpers did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Alpers come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Alpers

Gastroenterology · Saint Louis, MONPI 1740207208

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $609,211 of the $616,196 with a category attached, or 98.9%. 6 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 33.4% of the total. Reporting peaked in 2019 at $163,798 and has fallen 83.5% since, to $27,050 in 2025. Among gastroenterology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$616,196in general payments, 2019–2025

Across 248 payments — averaging $2484.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$206K
Otsuka Pharmaceutical Development & Commercialization, Inc.$193K
GSK$123K
Pfizer$75K
AstraZeneca$13K
Madrigal Pharmaceuticals$6K

$24,350in research payments, 2019–2025

Across 5 payments — averaging $4870.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$21K
AstraZeneca$4K

What the payments were for

Consulting fees$609,21199%
Travel & lodging$5,9931%
Food & beverage$9930%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	65	$206,040
Otsuka Pharmaceutical Development & Commercialization, Inc.	85	$193,468
GSK	34	$122,514
Pfizer	21	$75,460
AstraZeneca	20	$12,714
Madrigal Pharmaceuticals	23	$6,000

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SAMSCA$104,268
TOLVAPTAN$99,982
JYNARQUE$16,918
REZDIFFRA$6,000
TAKHZYRO$1,200

How this compares

$616,196 in reported general payments places this provider in the 95th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri →

Other gastroenterology in Saint Louis

Gregory SayukSaint Louis$1.1M
Katie SchroederSaint Louis$730K
Parakkal DeepakSaint Louis$205K
Mauricio Lisker MelmanSaint Louis$179K
Matthew CiorbaSaint Louis$156K
Bruce BaconSaint Louis$138K
Jeffrey CrippinSaint Louis$120K
Vladimir KushnirSaint Louis$118K
Kayci Huff-HardySaint Louis$116K
Rajesh KeswaniSaint Louis$109K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →